Eli Lilly and Co. and Transition Therapeutics, Inc. have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition’s gastrin-based therapies, including the lead compound TT-223, which is currently in early Phase II development. Gastrin-based therapies are a new class of potential disease-modifying therapies for patients with diabetes, and have shown sustained improvement in glycemic control in early clinical studi...